ASH Annual Meeting 5 – 8 December 2020 Virtual Meeting visit conference website
About Peggy Bickerton
This author has yet to write their bio.
Meanwhile lets just say that we are proud Peggy Bickerton contributed a whooping 49 entries.
32nd EORTC-NCI-AACR Symposium 24 – 25 October 2020 Virtual Meeting visit conference website
NCI has announced availability to investigators of oral decitabine and cedazuridine tablets for clinical and nonclinical study proposals under the CRADA The collaboration is intended to study oral decitabine and cedazuridine tablets in a range of tumor types Pleasanton, CA, – October 28th, 2020. – Astex Pharmaceuticals, Inc., a wholly owned subsidiary of Otsuka […]
Acute Leukemia Forum 2020 15 – 16 October 2020 La Jolla, CA visit conference website
Guadecitabine did not meet the primary endpoint of improvement in overall survival versus comparator in either study Evaluating options for the future of the guadecitabine program Pleasanton, CA and Tokyo, Japan, October 14th, 2020. Astex Pharmaceuticals, Inc., a member of the Otsuka group of companies, and Otsuka Pharmaceutical Co., Ltd., today announce top-line results of […]
Eleventh American Conference on Pharmacometrics (ACoP2020) 4 – 7 October 2020 Aurora, CO visit conference website
ACCP Annual Meeting 21 – 23 September 2020 Virtual Meeting visit conference website
SOHO Annual Meeting 9 – 12 September 2020 Virtual Meeting visit conference website
Pleasanton, CA, and Houston, TX – September 8th, 2020. – Astex Pharmaceuticals, Inc., a wholly owned subsidiary of Otsuka Pharmaceutical Co. Ltd., based in Tokyo, Japan, and The University of Texas MD Anderson Cancer Center today announces a strategic collaboration agreement aimed at accelerating the clinical evaluation of Astex’s pipeline of products for patients with […]
Pleasanton, CA, August 31st, 2020. Astex Pharmaceuticals, Inc., a wholly owned subsidiary of Otsuka Pharmaceutical Co., Ltd., based in Tokyo, Japan, announces that the US Food & Drug Administration (FDA) has granted orphan drug designation for the company’s novel, orally administered non-peptidomimetic antagonist of the cellular and X-linked inhibitors of apoptosis proteins (cIAP1/2 and XIAP), […]